India  

FDA Grants Moderna's COVID-19 Vaccine Full Approval

Video Credit: Wibbitz Top Stories - Duration: 01:30s - Published
FDA Grants Moderna's COVID-19 Vaccine Full Approval

FDA Grants Moderna's COVID-19 Vaccine Full Approval

FDA Grants Moderna's, COVID-19 Vaccine , Full Approval.

On January 31, Moderna announced that its COVID-19 vaccine has been granted full approval by United States health regulators.

.

On January 31, Moderna announced that its COVID-19 vaccine has been granted full approval by United States health regulators.

.

The Associated Press reports that since its emergency authorization over a year ago, the vaccine has already been given to tens of millions of Americans.

.

The Associated Press reports that since its emergency authorization over a year ago, the vaccine has already been given to tens of millions of Americans.

.

In August of 2021, the FDA granted full approval to Pfizer's vaccine.

The Associated Press reports that over 211 million Americans are fully vaccinated - about 63% of the population.

.

The Associated Press reports that over 211 million Americans are fully vaccinated - about 63% of the population.

.

Approximately 86 million people have received at least one dose of a booster.

.

According to the AP, vaccinations peaked at over 3 million doses were distributed per day last spring.

Now, daily doses average less than 750,000.

.

The AP reports that the vaccine's initial emergency approval was based on a study that tracked 44,000 people for two months.

Moderna then continued that study to complete longer six-month-long studies normally required for full approval.

.

The FDA reportedly monitored for serious side effects that have proven to be extremely rare.

.

The FDA reportedly monitored for serious side effects that have proven to be extremely rare.

.

Last fall, the FDA delayed approving Moderna's vaccine for use in 12 to 17 year olds as it investigated the risk of heart inflammation in young men.

.

Last fall, the FDA delayed approving Moderna's vaccine for use in 12 to 17 year olds as it investigated the risk of heart inflammation in young men.


You Might Like


💡 newsR Knowledge: Other News Mentions

Moderna Moderna American biotechnology company

Moderna Sues Pfizer Over COVID Vaccine Patents [Video]

Moderna Sues Pfizer Over COVID Vaccine Patents

Moderna Sues Pfizer , Over COVID Vaccine Patents. Moderna Sues Pfizer , Over COVID Vaccine Patents. AP reports that Moderna is suing Pfizer and BioNTech for allegedly copying its technology. . On Aug. 26, Moderna said the companies' vaccine, Comirnaty, infringes on patents filed years ago for its own vaccine, Spikevax. . On Aug. 26, Moderna said the companies' vaccine, Comirnaty, infringes on patents filed years ago for its own vaccine, Spikevax. . Stephane Bancel, Moderna CEO, claims the vaccine developer was first to create the mRNA technology used in the current vaccines. . Stephane Bancel, Moderna CEO, claims the vaccine developer was first to create the mRNA technology used in the current vaccines. . The company claims to have started developing the technology in 2010, which helped it to quickly manufacture its COVID vaccine. The technology is vastly different from the way vaccines typically work. . AP reports that a Pfizer spokesperson said the company has yet to be served. Moderna is not requesting for Comirnaty to be removed from the market because of the importance of vaccine access. The company is also not trying to prevent future sales. . We are filing these lawsuits to protect the innovative mRNA technology platform that we pioneered, invested billions of dollars in creating, and patented during the decade preceding the COVID-19 pandemic. , Stephane Bancel, Moderna CEO, via statement

Credit: Wibbitz Top Stories    Duration: 01:30Published
U.K. Approves Vaccine Booster That Targets Omicron [Video]

U.K. Approves Vaccine Booster That Targets Omicron

U.K. Approves , Vaccine Booster , That Targets Omicron. The United Kingdom has become the first country to approve vaccine boosters specifically designed to counter the omicron variant of COVID-19. The United Kingdom has become the first country to approve vaccine boosters specifically designed to counter the omicron variant of COVID-19. NPR reports that the decision paves the way for people in the U.K. to receive their shots early in the fall season. The Moderna vaccine booster is "bivalent," meaning that it combines two different versions of the vaccine. Half of the mix is aimed at the original strain of COVID, while the other half is formulated to fight the original omicron variant. What this bivalent vaccine gives us is a sharpened tool in our armory to help protect us against this disease as the virus continues to evolve, Dr. June Raine, Head of the U.K.'s Medicines and Healthcare Products Regulatory Agency, via NPR. What this bivalent vaccine gives us is a sharpened tool in our armory to help protect us against this disease as the virus continues to evolve, Dr. June Raine, Head of the U.K.'s Medicines and Healthcare Products Regulatory Agency, via NPR. According to researchers in the U.K., the omicron booster "triggers a strong immune response" that defends against both the 2020 strain of COVID and omicron. According to researchers in the U.K., the omicron booster "triggers a strong immune response" that defends against both the 2020 strain of COVID and omicron. NPR points out that the combo booster differs from the omicron-specific booster which officials in the United States hope to roll out this fall. The U.S. FDA has requested vaccine developers to target later omicron variants BA.4 and BA.5. Those two strains currently make up a majority of cases in the U.S. According to NPR, officials hope to authorize omicron-specific boosters by mid-September

Credit: Wibbitz Top Stories    Duration: 01:31Published

Food and Drug Administration Food and Drug Administration Agency of the US Department of Health and Human Services

5 Tips for Keeping Your Caffeine Consumption in Check [Video]

5 Tips for Keeping Your Caffeine Consumption in Check

5 Tips for Keeping , Your Caffeine Consumption in Check. Caffeine is a stimulant found in coffee, tea and other products. . LifeHack reports that at least 80% of the world's population consumes caffeine from different sources daily. While moderate consumption is good, too much can be harmful. . The U.S. Food and Drug Administration says that adults can safely consume 400 milligrams, or 4 to 5 cups of coffee, a day. Here are some tips to moderate your caffeine consumption. . 1. Understand the dangers of consuming too much caffeine. . Too much caffeine can be harmful to your body, heart, liver and skin. . 2. Set limits to how many caffeinated drinks you have in a day and stick with it. . 3. Avoid loading your coffee with sugar, as it could lead to other unwanted side effects. 4. Don't have caffeine after 2 P.M., as it can negatively affect your sleep cycle. 5. Don’t be afraid to cut back. . A lifestyle change can be overwhelming, but don't be scared.

Credit: Wibbitz Top Stories    Duration: 01:24Published
Drugmaker Announces Promising Results of Potential Alzheimer's Treatment [Video]

Drugmaker Announces Promising Results of Potential Alzheimer's Treatment

Drugmaker Announces , Promising Results of Potential , Alzheimer's Treatment. On September 28, shares of Biogen and other drugmakers researching Alzheimer's disease skyrocketed after Japan's Eisai Co. announced promising late-stage study results. 'Time' reports that the company said its potential treatment appeared to slow the progress of the fatal disease. On September 27, Eisai announced the results of a global study of nearly 1,800 people with early-stage Alzheimer's. According to the drugmaker, early results show that the treatment reduced patients' decline by 27% over 18 months. Eisai Co. also announced plans to discuss the trial's full results at a conference in November. 'Time' reports that the company plans to publish the findings in a peer-reviewed medical journal. Meanwhile, the company has already sought accelerated approval from the U.S. Food and Drug Administration. 'Time' reports that the regulatory agency is expected to make a decision by early 2023. The Alzheimer's Association released a statement calling the study's findings the most encouraging to date for potential treatments. Following the announcement, shares of Biogen Inc. jumped over 50% in premarket trading to top $300

Credit: Wibbitz Top Stories    Duration: 01:30Published
Biden Admin To Suggest Nutrition Labels on Front of Food Products to Improve Health [Video]

Biden Admin To Suggest Nutrition Labels on Front of Food Products to Improve Health

Biden Admin to Suggest Nutrition Labels , on Front of Food Products to Improve Health. NBC News reports that on Sept. 27, the White House announced that the FDA will look into a new food labeling system. The administration hopes that the proposed front-of-package labeling approach will help “to shift our health care system away from just treating disease to preventing it.” . The administration hopes that the proposed front-of-package labeling approach will help “to shift our health care system away from just treating disease to preventing it.” . It would aim "to help consumers, particularly those with lower nutrition literacy, quickly and easily identify foods that are part of a healthy eating pattern." . The Biden administration said it would also suggest an update to the criteria by which food can be deemed "healthy" on food packaging. . The Biden administration said it would also suggest an update to the criteria by which food can be deemed "healthy" on food packaging. . NBC News reports that in May, President Biden set a goal to eradicate hunger and increase healthy eating and exercise by 2030. Food access and affordability are also top priorities for the administration. . According to the Department of Agriculture, SNAP will begin supplying an extra $26 a month per person on average on Oct. 1. The White House also seeks to increase access to free, healthy school meals for 9 million more kids by 2032. NBC News reports that the White House is preparing to host its first Conference on Hunger, Nutrition and Health in over 50 years on Sept. 28

Credit: Wibbitz Top Stories    Duration: 01:31Published
FDA Admits Delays in Response to Baby Formula Shortage [Video]

FDA Admits Delays in Response to Baby Formula Shortage

FDA Admits Delays in Response , to Baby Formula Shortage. The Food and Drug Administration (FDA) released a report detailing its response to the shortage on Sept. 22. The 10-page report cites several aspects of the agency's response. including poor data-sharing systems, staffing shortages and lack of oversight for the specific manufacturing and supply chain protocols. For things that are critical to the public health, if you don’t have some understanding of how all the pieces fit together, , Robert Califf, FDA Commissioner, via NBC News. ... then when you get into a crisis or a shortage you have a real problem, Robert Califf, FDA Commissioner, via NBC News. To a large extent that’s what happened here, Robert Califf, FDA Commissioner, via NBC News. The report arrives several months after a baby formula manufacturing plant in Michigan was closed because of safety issues. An FDA investigation into a whistleblower's warning about the plant didn't begin until months after the complaint was filed. Consumer advocates say the FDA's report falls short of what is needed to fully address systemic issues. This internal evaluation treats the symptoms of the disease rather than offering a cure, Scott Faber, Environmental Working Group, via NBC News. Nothing in this evaluation addresses the fragmented leadership structure that led to critical communication failures, Scott Faber, Environmental Working Group, via NBC News. U.S. inventories of baby formula have increased from 69 percent in July to 80 percent. Imports of various baby formula products have increased significantly since May. The FDA's food division is currently under an external review seeking answers to "questions about the structure, function, funding and leadership."

Credit: Wibbitz Top Stories    Duration: 01:31Published
Juul Ordered to Pay $440 Million in Teen Vaping Settlement [Video]

Juul Ordered to Pay $440 Million in Teen Vaping Settlement

Juul Ordered to Pay , $440 Million, in Teen Vaping Settlement. Electronic cigarette maker Juul Labs will pay a $440 million settlement to end a two-year investigation into the company's marketing of its vaping products. 'The Guardian' reports that the 33-state investigation comes after the company was blamed for sparking a national surge in teen vaping. The nearly $440 million deal was announced on September 6 by William Tong, the Connecticut attorney general. The nearly $440 million deal was announced on September 6 by William Tong, the Connecticut attorney general. The investigation reportedly looked into Juul's early promotions and claims regarding the safety and benefits of its product as a smoking alternative. The investigation reportedly looked into Juul's early promotions and claims regarding the safety and benefits of its product as a smoking alternative. Following the settlement, Juul still faces nine separate lawsuits from other states. In addition to these state lawsuits, the company is also facing hundreds of personal suits brought on behalf of consumers who say they became addicted to the company's products. In addition to these state lawsuits, the company is also facing hundreds of personal suits brought on behalf of consumers who say they became addicted to the company's products. Through this settlement, we have secured hundreds of millions of dollars to help reduce nicotine use and forced Juul to accept a series of strict injunctive terms to end youth marketing and crack down on underage sales, William Tong, Connecticut attorney general, via 'The Guardian'. 'The Guardian' reports that the $438.5 million settlement will be paid out over a period of six to ten years. This summer, the Food and Drug Administration moved to ban all Juul vaping products from the market. . An ongoing FDA review is one part of a sweeping effort to regulate the multimillion-dollar vaping industry following years of regulatory delay

Credit: Wibbitz Top Stories    Duration: 01:31Published

COVID-19 COVID-19 Contagious disease caused by SARS-CoV-2

Covid-19 Update: India reports 3,011 fresh Covid-19 cases in 24 hours | OneIndia News *News [Video]

Covid-19 Update: India reports 3,011 fresh Covid-19 cases in 24 hours | OneIndia News *News

In yet another dip in the number of Covid-19 cases, India reported 3,011 fresh covid-19 infections within a span of 24 hours. With this the total number of covid-19 infections in the country surged to 4,45,97,498. Active Covid cases decline to 36,126 from 37,444, according to the data released by the Union Health Ministry. #Covid19 #Covid19Cases #India

Credit: Oneindia    Duration: 02:07Published
Covid-19 Update: India reports 3,805 fresh Covid cases in 24 hours | OneIndia News *News [Video]

Covid-19 Update: India reports 3,805 fresh Covid cases in 24 hours | OneIndia News *News

The country saw another decline in the active covid-19 cases as the cases fell below the 40,000 mark and declined to 38,293. India recorded a slight dip in Covid-19 cases after reporting 3,947 cases a day before. 3,805 fresh covid cases were added to the total tally of Covid-19 infections in the country on Friday. With this, the total number of Covid-19 cases jumped to 4,45,91,112. #CovidUpdate #Covid19Cases #Live

Credit: Oneindia    Duration: 02:22Published

Moderna COVID-19 vaccine Moderna COVID-19 vaccine RNA COVID-19 vaccine


Pfizer Pfizer American multinational pharmaceutical and biotechnology corporation

Pfizer's chief executive tests positive for COVID-19 for second time in two months

Pfizer's chief executive has tested positive for COVID-19 for the second time in two months.
Sky News
Pfizer Announces $5.4 Billion Deal to Acquire Global Blood Therapeutics [Video]

Pfizer Announces $5.4 Billion Deal to Acquire Global Blood Therapeutics

Pfizer Announces , $5.4 Billion Deal , to Acquire Global Blood Therapeutics. Pfizer has announced a $5.4 billion deal for the blood disorder drugmaker. NBC reports that the news marks the latest attempt by Pfizer to combat declining demand for COVID-19 products as case numbers fall. The company has seen an unprecedented rise in sales since the global rollout of its COVID-19 vaccine. However, sales have begun to slow since the height of the pandemic. NBC reports that Pfizer is now seeking acquisitions that have the potential to boost sales by billions by the end of the decade. In May, Pfizer acquired migraine drugmaker Biohaven Pharmaceutical Holding for $11.6 billion. The company also recently completed a $6.7 billion deal to purchase Arena Pharmaceuticals. According to NBC, the acquisition of Global Blood Therapeutics would allow Pfizer to boost sales of Oxybryta. In 2019, Oxybryta was first approved as a treatment for Sickle Cell Disease. . An estimated 70,000 to 100,000 people in the United States are affected by Sickle Cell Disease, which is an inherited blood disorder. Following the announcement of the deal, shares of Global Blood rose 4.5%.

Credit: Wibbitz Top Stories    Duration: 01:31Published

Related videos from verified sources

PSAKI Biden will continue to pressure employers to institute their own vaccine mandates [Video]

PSAKI Biden will continue to pressure employers to institute their own vaccine mandates

Private employers do not have the legal authority to mandate experimental mRNA covid-19 SARS-COV-2 inoculations upon their employees. With the decision from the United States supreme court in a 6-3..

Credit: Rumble     Duration: 00:36Published
CDC Says Fully-Vaccinated Can Now Receive Pfizer Boosters After 5 Months [Video]

CDC Says Fully-Vaccinated Can Now Receive Pfizer Boosters After 5 Months

CDC Says Fully-Vaccinated , Can Now Receive Pfizer Boosters, After 5 Months. On Jan. 4, the CDC announced that those who've been fully vaccinated with Pfizer's COVID-19 vaccine can now receive a..

Credit: Wibbitz Top Stories     Duration: 01:30Published